No products in the cart.

Compare
Home/Compare

Cannabinoid Comparison Hub: Pharmacology and the EU Position

There are over a hundred cannabinoids in cannabis and around ten of them are sold to consumers. They act at different receptors, in different directions, and their evidence bases differ enormously, from three regulatory-grade trials at one end to zero human studies at the other.

FDA structure and function language No disease claims
100% Organic Third Party Tested 30-Day Money Back Guarantee Highest Quality Full Spectrum Global Shipping
100% Organic Third Party Tested 30-Day Money Back Guarantee Highest Quality Full Spectrum Global Shipping

What actually separates these compounds.

Three things separate these compounds, and none of them is a flavour preference. Read them before you read any comparison, because they decide what a claim is worth.

Different receptors

CBD does not activate CB1 at all. THC is a partial agonist at it. CBC prefers CB2. The target decides the effect.

Different directions

Two cannabinoids can meet the same receptor and pull opposite ways. THCV blocks CB1 at low doses and activates it at high ones.

Different evidence

From three regulatory-grade trials at one end to zero human studies at the other. Most minor cannabinoid data is in vitro or rodent.

Start with the question you actually have.

Most comparison content treats cannabinoids as a menu of wellness options. They are not that. They act at different receptors, in different directions, and their evidence bases differ enormously.

Reishi vs Ashwagandha
A bracket fungus against a nightshade root. Both have published liver case reports, and one of them is prohibited in food supplements in Denmark.
Read comparison →
Lion’s Mane vs Ashwagandha
One is a fungus, the other a nightshade root carrying a liver injury signal and a Danish prohibition. Here is what has been measured in each of them.
Read comparison →
Maitake vs Shiitake
Maitake is Grifola frondosa, shiitake is Lentinula edodes. Both are foods, both have one small human trial, and undercooked shiitake causes a rash.
Read comparison →
Turkey Tail vs Reishi
Turkey tail is Trametes versicolor and reishi is Ganoderma lucidum. Here is what has been measured in each, and what the human trials did not find.
Read comparison →
Chaga vs Turkey Tail
Chaga is a sterile conk high in oxalate with no trials in people. Turkey tail's trial record belongs to PSK, a preparation licensed in Japan.
Read comparison →
Cordyceps vs Reishi
Cordyceps is a category of fungi marked by cordycepin or adenosine. Reishi is a single species, Ganoderma lucidum, measured by beta-glucans.
Read comparison →
Full Spectrum vs Broad Spectrum vs Isolate
Full spectrum keeps the plant's THC, broad spectrum removes it, isolate is 99 percent CBD. What each one contains, and what has been measured.
Read comparison →
Reishi vs Chaga
Reishi is a Ganoderma lucidum fruiting body that needs two solvents. Chaga is the sterile conk of Inonotus obliquus, and it is high in oxalate.
Read comparison →
CBD Isolate vs Distillate
CBD isolate is 99 percent pure cannabidiol; distillate is a 70 to 90 percent cannabinoid cut. What each retains, and what has actually been measured.
Read comparison →
CBDA vs THCA
CBDa and THCa are the acids hemp actually makes. Neither has been tested in a controlled human trial. What was actually measured, and what was not.
Read comparison →
Lion’s Mane vs Reishi vs Cordyceps
One species is certain, one is misnamed, one is a whole genus. Lion's mane, reishi and cordyceps on compounds, extraction, trials and UK novel food law.
Read comparison →
CBGA vs CBG
CBGa is the precursor every cannabinoid comes from. CBG has one small randomised human trial; CBGa has none. What each one has been measured doing.
Read comparison →

No comparison matches that search.

The honest summary.

Every claim on this table is sourced on the individual pages. Binding affinity numbers for the minor cannabinoids are genuinely inconsistent between labs, so assay context matters.

Compound
CB1 receptor
CB2 receptor
Other target
Human evidence
Intoxicating
Where it comes from
CBD
No activation. Negative allosteric modulator
Ki 240 nM, low efficacy
ENT1 transporter under 250 nM; TRPA1 ~0.09 μM
Strong in rare epilepsy, negative in pain
No
CBDA, decarboxylated
THC
Partial agonist, Ki 20 to 36 nM
Ki 31 to 52 nM
TRPA1, 0.23 μM
Extensive, including approved medicines
Yes
THCA, decarboxylated
CBG
Weak, Ki around 1.3 μM
Weak partial, Ki 490 nM
Alpha-2 adrenoceptor, EC50 0.2 nM
One human trial
No
CBGA, the parent precursor
CBN
Weak partial, 29 percent max effect
Negligible
TRPA1, 0.18 μM
One polysomnography trial
Weakly, very high doses
Oxidation of THC
CBC
Disputed between studies
CB2-preferring, Ki 27 nM
TRPA1, approximately 0.09 μM
None
No
CBCA, decarboxylated
CBDa
Inactive, Ki above 10 μM
Low efficacy
COX-2, EC50 2 μM, 9-fold selective
No controlled trials
No
Native plant product
CBDV
Inactive
Ki 140 nM, EC50 5.0 nM
TRPA1, 0.42 μM
Two designed trials, both negative
No
CBDVA, propyl series
THCV
Antagonist at low dose, agonist at high
Partial agonist, Ki 47 to 63 nM
5-HT1A positive modulation
Limited early-stage work
Dose-dependent
THCVA, propyl series
THCa
Weak, EC50 above 10 μM
Disputed
PPAR-gamma, potent
Essentially none in humans
No, until heated
Native plant product
Delta-8 THC
Partial agonist, Ki around 36 nM
Around 50 nM, same as delta-9
Same profile as delta-9
Minimal; EFSA equates potency to delta-9
Yes
Acid conversion, usually from CBD
Showing 6 of 10 compounds

Important context: Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg. No trial evidence supports scaling those findings down.

Eight cannabinoids, eight evidence bases.

Receptor figures are in vitro and vary between laboratories. The evidence bar counts human trials, not cell studies.

CBD Non-intoxicating
Cannabidiol
CB1No activation
CB2Ki 240 nM
OriginCBDA, decarboxylated
Human evidence Dozens of trials
THC Intoxicating
Delta-9-tetrahydrocannabinol
CB1Partial agonist, 20 to 36 nM
CB2Ki 31 to 52 nM
OriginTHCA, decarboxylated
Human evidence Extensive
CBG Non-intoxicating
Cannabigerol
CB1Weak, Ki 1.3 μM
CB2Weak partial, 490 nM
OriginCBGA, the precursor
Human evidence One trial
CBN Intoxicating
Cannabinol
CB1Weak partial, 29 percent
CB2Negligible
OriginOxidation of THC
Human evidence One sleep trial
CBC Non-intoxicating
Cannabichromene
CB1Disputed
CB2CB2-preferring, 27 nM
OriginCBCA, decarboxylated
Human evidence None
CBDa Non-intoxicating
Cannabidiolic acid
CB1Inactive above 10 μM
CB2Ki 12 nM, low efficacy
OriginNative plant product
Human evidence None controlled
CBDV Non-intoxicating
Cannabidivarin
CB1Inactive
CB2Ki 140 nM
OriginCBDVA, propyl series
Human evidence Two, both negative
THCV Intoxicating
Tetrahydrocannabivarin
CB1Antagonist low, agonist high
CB2Partial, 47 to 63 nM
OriginTHCVA, propyl series
Human evidence Limited

One precursor. Several directions.

Understanding the biosynthesis makes the table easier to read. Cannabis makes one precursor, CBGA. Three enzymes compete for it. THCA synthase produces THCA. CBDA synthase produces CBDA. CBCA synthase produces CBCA. Whatever CBGA is left becomes CBG.

Heat and time then strip a carbon dioxide group from each acid, giving THC, CBD, CBC and CBG.

One precursor. Several directions.
Two compounds sit outside that scheme

CBN has no synthase; it is what THC becomes when it oxidises. Delta-8 THC is barely present in natural hemp and is generally manufactured by acid conversion from CBD.

And a separate branch makes the varins

Built from a shorter starting molecule, it produces CBDV and THCV. That branch is genetically segregated, which is why varin content is rare in ordinary hemp.

Three things worth knowing first.

Each one changes what a claim on the pages ahead is actually worth.

Three things worth knowing first.
01
The dose gap

Human trials showing effects for CBD used 100 to 1,600 mg a day. Consumer products typically deliver 10 to 50 mg, and EFSA’s provisional safe level sits at around 2 mg. No trial evidence supports scaling those findings down.

02
Most minor cannabinoid data is preclinical

CBC, CBDa and THCa have essentially no controlled human data at all. Binding affinity numbers are also genuinely inconsistent between labs, and any single figure quoted without its assay context is misleading.

03
The entourage effect is not established

Two studies designed specifically to test whether cannabis terpenes modulate cannabinoid receptor activity found they do not. A 2024 scoping review concluded there is limited evidence for it as a stable and predictable phenomenon.

Why we publish it this way

We grow our own hemp in Europe, run our own supercritical CO2 extraction and publish a third-party certificate of analysis for every batch. Under EU rules, that measured laboratory data is close to the entirety of what we are lawfully permitted to tell you about a cannabinoid product.

It is also, in our view, the most useful thing we could tell you. A company selling these compounds has an obvious incentive to overstate what they do. We would rather publish the trials that failed alongside the ones that succeeded.

What European law permits anyone to say

This is the section most CBD sites omit, and its absence is usually how you can tell a page has not been written carefully.

Under Regulation (EC) No 1924/2006, a health claim may only be made if it appears on the Union list of authorised claims. No health claim for CBD, cannabidiol, hemp extract or any cannabinoid is authorised. None.

Article 10(3) reaches further than most people realise. References to general, non-specific benefits are permitted only alongside a specific authorised claim. Because no cannabinoid claim exists, phrases such as “supports wellbeing”, “helps you relax”, “for balance” or “supports the endocannabinoid system” are not lawful on a cannabinoid product in the EU either.

Regulation (EU) No 1169/2011, Article 7(3), separately prohibits attributing to any food the property of preventing, treating or curing a human disease. Under Directive 2001/83/EC, a product presented as having therapeutic properties can be reclassified as an unauthorised medicinal product, which is a considerably more serious outcome than a labelling breach.

Enforcement authorities treat implied claims as claims: product names, category names such as a “sleep range”, imagery, testimonials, influencer content, meta descriptions and links to clinical studies about effects.

What remains lawful is factual information: botanical origin, extraction method, measured cannabinoid content, purity, third-party laboratory analysis, allergen and ingredient declarations, and instructions for use.

Every page in this hub is built from that narrow palette. It is why they describe receptors and trials rather than benefits.

 

The EU regulatory position, in short

CBD and all cannabinoid-containing extracts are unauthorised novel foods under Regulation (EU) 2015/2283. No CBD novel food has been authorised anywhere in the EU. Hemp seeds, hemp seed oil and hemp seed protein are not novel and are unaffected.

EFSA published a provisional safe level in February 2026: 0.0275 mg per kilogram of body weight per day, roughly 2 mg for a 70 kg adult, for CBD isolate of at least 98 percent purity. Safety could not be established for anyone under 25, for pregnant or breastfeeding women, or for people taking medication.

The Kanavape judgment, stated correctly. In Case C-663/18 the Court of Justice held that CBD lawfully produced from the whole plant is not a narcotic drug, and that member states cannot ban lawfully produced CBD on narcotics grounds alone without justification. It did not authorise CBD as a food. Novel food, food information and medicines rules apply independently. The frequently repeated line that the EU Court made CBD legal across Europe conflates narcotics law with food law.

THC limits are three separate things. The 0.3 percent figure is a cultivation eligibility criterion for hemp varieties, raised from 0.2 percent in January 2023. Regulation (EU) 2022/1393 sets THC maxima only for hemp seed products, at 3.0 mg/kg and 7.5 mg/kg for the oil. Finished-product limits for extracts are national and diverge sharply.

Member states differ substantially. Germany’s BVL considers CBD food supplements not marketable. Denmark requires novel food authorisation and publishes THC action limits. Sweden combines novel food classification with a narcotics ruling covering THC-containing extracts. Spain’s enforcement has channelled the category into external-use products. The Netherlands operates an informal tolerance conferring no legal certainty.

01
Our own fields Organically grown hemp, cultivated by us rather than bought in.
02
Our own extraction CO2 extraction in our own labs, so the process is ours end to end.
03
A COA per batch Measured cannabinoid content published against the code on your bottle.
04
Negative results too We publish the trials that failed alongside the ones that worked.

References

Each comparison page carries its own reference list. The primary sources behind the master table are:

01 Zagzoog A et al. Sci Rep 2020;10:20405.
02 Walsh KB, McKinney AE, Holmes AE. Front Pharmacol 2021;12:777804
03 De Petrocellis L et al. Br J Pharmacol 2011;163:1479-1494.
04 Pertwee RG. Br J Pharmacol 2008;153:199-215.
05 Ibeas Bih C et al. Neurotherapeutics 2015;12:699-730.
06 EFSA CONTAM Panel. EFSA Journal 2025;23(11):e9735.
07 EFSA. Provisional safe level for cannabidiol. EFSA Journal 2026;24:9862
08 Court of Justice of the European Union, Case C-663/18, 19 November 2020
09 Regulation (EC) No 1924/2006 and Commission Regulation (EU) No 432/2012.